Search results
Showing 1351 to 1400 of 2026 results for work
Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]
Discontinued Reference number: GID-TAG482
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
Discontinued Reference number: GID-TA10606
In development Reference number: GID-TA11801 Expected publication date: TBC
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Discontinued Reference number: GID-TA11228
Discontinued Reference number: GID-TA10072
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]
Discontinued Reference number: GID-TAG337
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
In development Reference number: GID-TA11759 Expected publication date: TBC
In development Reference number: GID-TA11607 Expected publication date: TBC
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
This quality standard covers improving the quality of the patient experience for people who use adult NHS services. It describes high-quality care in priority areas for improvement.
View quality statements for QS15Show all sections
Sections for QS15
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Contacts for ongoing care
- Quality statement 3: Information exchange
- Quality statement 4: Individualised care
- Quality statement 5: Preferences for sharing information
- Quality statement 6: Decision making
- Update information
This quality standard covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover areas of national policy, such as the UK Bacillus Calmette-Guérin (BCG) immunisation programme.
View quality statements for QS141Show all sections
Sections for QS141
- Quality statements
- Quality statement 1: Latent tuberculosis testing for people from high-incidence countries
- Quality statement 2: Latent tuberculosis testing for adults with HIV
- Quality statement 3: Rapid diagnosis of pulmonary tuberculosis
- Quality statement 4: Assessment
- Quality statement 5: Directly observed therapy
- Quality statement 6: Accommodation
- Update information
For which people with impetigo are antiseptics as effective as antibiotics?
A faster recovery is also likely to mean less time off school, nursery or work. It was not clear in the evidence reviewed if impetigo...
Discontinued Reference number: GID-TAG280
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
Discontinued Reference number: GID-TAG433
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
Discontinued Reference number: GID-TAG425
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
Discontinued Reference number: GID-TAG424
Discontinued Reference number: GID-TA10233
Generalised anxiety disorder and panic disorder in adults: management (CG113)
This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.
New pharmaceutical treatments for non-Alzheimer dementias [ID380]
Discontinued Reference number: GID-TAG369
Discontinued Reference number: GID-TA10033
Discontinued Reference number: GID-TAG437
Discontinued Reference number: GID-TA10531
In development Reference number: GID-TA11585 Expected publication date: TBC
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
Discontinued Reference number: GID-TAG507
Discontinued Reference number: GID-TA10133
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Discontinued Reference number: GID-TA11109
Phentermine with topiramate for the treatment of obesity and overweight [ID543]
Discontinued Reference number: GID-TAG439
Discontinued Reference number: GID-TA11277
Discontinued Reference number: GID-TA10568
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
Discontinued Reference number: GID-TA10413
In development Reference number: GID-MT538 Expected publication date: TBC
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued Reference number: GID-TA10416
In development Reference number: GID-TA11760 Expected publication date: TBC
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued Reference number: GID-TA10180
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Discontinued Reference number: GID-TAG409
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088